Proteome Sciences secures further clinical contract
22nd Jun 2026 13:32
(Sharecast News) - Proteome Sciences said on Monday that it had secured a further significant clinical contract linked to its target engagement and chemoproteomics platform.
Read moreProteome secures third contract from US biopharma client
8th Dec 2025 09:39
(Sharecast News) - Proteome Sciences announced on Monday that it has secured a third contract from a US biopharmaceutical client for its mass spectrometry services, further expanding the company's role in supporting clinical development programmes.
Read moreProteome secures $1m-plus contract with US biopharma firm
21st Feb 2025 11:32
(Sharecast News) - Proteome Sciences announced on Friday that it has secured a contract worth over $1m from a US biopharmaceutical company for the use of its mass spectrometry services in an ongoing clinical trial.
Read moreProteome Sciences gives bullish outlook for 2025
23rd Dec 2024 11:56
(Sharecast News) - Shares in drug development services group Proteome Sciences rose on Monday after the company said 2024 results should reflect a good recovery and that its pipeline is looking strong for next year.
Read moreProteome Sciences swings to EBITDA loss, CEO steps down
13th Sep 2024 12:02
(Sharecast News) - Proteome Sciences announced a significant drop in first-half revenue and profit on Friday, alongside the departure of its chief executive.
Read moreProteome Sciences secures contract win with US biopharmaceutical firm
26th Apr 2024 09:45
(Sharecast News) - Contract proteomics service Proteome Sciences has secured a contract win from a US biopharmaceutical company using the company's mass spectrometry services for the analysis of samples for an on-going clinical trial.
Read moreProteome launches San Diego lab operations
2nd Jan 2024 14:44
(Sharecast News) - Proteomics services provider Proteome Sciences announced the installation and start of operations at its new laboratory in San Diego, California, on Tuesday.
Read moreProteome Sciences issues profit warning after project delays
1st Dec 2023 12:01
(Sharecast News) - Proteome Sciences, the AIM-listed protein sequencing contract research organisation, has warned it will swing to a net loss this year with full-year sales lower than expected.
Read moreProteome Sciences revenue, earnings dip in firist half
25th Aug 2023 09:11
(Sharecast News) - Proteome Sciences released its unaudited financial results for the first six months of the year on Friday, reporting an increase in its proteomics services revenues to £1.01m, from £0.85m a year earlier.
Read moreProteome Sciences to open new San Diego facility
12th May 2023 11:07
(Sharecast News) - Proteomics service provider Proteome Sciences announced its plan to expand operations into the United States on Friday, with a new facility to be located in San Diego, California.
Read moreProteome Sciences reports solid growth in 2022
4th Apr 2023 11:44
(Sharecast News) - Biotechnology company Proteome Sciences reported total revenues of £7.78m in its final results on Tuesday - a significant year-on-year increase from £5.13m.
Read moreProteome FY revenues rise, operating costs increase
20th Feb 2023 11:33
(Sharecast News) - Shares in contract proteomics services provider Proteome said on Monday that it now expects full-year operating costs to have risen amid, offsetting revenue growth amid an increased investment in staffing and equipment.
Read moreProteome gets milestone payment from Thermo Scientific
5th Jan 2023 16:31
(Sharecast News) - Proteome Group announced a milestone payment for sales of 'TMT' and 'TMTpro' on Thursday.
Read moreProteome reaches milestone in launch of proteomics service
3rd Aug 2022 15:33
(Sharecast News) - Proteome Sciences has completed its next milestone towards the launch of 'single cell proteomics' services, it announced on Wednesday, dubbed 'SysQuant SCP'.
Read moreProteome Sciences maintains strong order book
16th May 2022 13:35
(Sharecast News) - Proteome Sciences said in an update on Monday that it had maintained a strong order book after recording a small profit in 2021.
Read more